Results 1 to 10 of about 29,283 (270)
Circulating tumor DNA (ctDNA) Detection via electrochemical Biosensing Tools [PDF]
MANAS: Journal of EngineeringCancer is characterized by the presence of mutated alleles in DNA, leading to the formation of tumors. A delayed diagnosis of this condition can result in fatal outcomes, making it a significant global cause of mortality.
Sonya Sahin, Nimet Yıldırım Tirgil
doaj +2 more sources
Advances in Laboratory MedicineEl análisis molecular del gen receptor del factor de crecimiento epidérmico (EGFR) resulta fundamental a la hora de seleccionar una terapia dirigida para el carcinoma pulmonar no microcítico avanzado (CPNM).
Fernández-Galán Esther +1 more
doaj +1 more source
Advances in Clinical Application of ctDNA in Tumor Detection, Screening, Prognosis and Treatment
Zhongliu Fangzhi Yanjiu, 2020 Circulating tumor DNA (ctDNA) is a tumor-derived fragmented DNA in blood and is a characteristic marker of tumor. Through the correlative detection of ctDNA, the trace information of the tumor in the blood of the patients can be detected, and the ...
LIU Yong
doaj +1 more source
Advances in Laboratory MedicineEpidermal growth factor receptor gene (EGFR) molecular testing is essential for guiding targeted therapies in patients with advanced non-small cell lung cancer (NSCLC). Between 15 and 40 % of patients with NSCLC carry mutations in EGFR that are sensitive
Fernández-Galán Esther +1 more
doaj +1 more source
Cancer Management and Research, 2021 Shaohua Guo,1,2,* Yumeng Ye,3,* Xinyi Liu,4 Yuan Gong,5 Mingyan Xu,4 Lele Song,4,6 Hongyi Liu1 1Department of General Surgery, The First Medical Center of the Chinese PLA General Hospital, Beijing, People’s Republic of China; 2Department of ...
Guo S +6 more
doaj
Journal of Laboratory MedicineCirculating tumor DNA (ctDNA) assays play an increasingly important role in cancer management. A new version of TruSight Oncology 500 (TSO500) ctDNA, v2, was recently released, and the recommended DNA input was decreased to 20 ng from 30 ng in the prior ...
Lee Cheonghwa +3 more
doaj +1 more source
Response-adaptive breast cancer care in the grey zones: integrating ER and HER2 targeted PET, FDG PET/CT under immunotherapy, and ctDNA kinetics [PDF]
Exploration of Targeted Anti-tumor TherapyBreast cancer management increasingly hinges on decisions made in “grey zones” where tissue sampling is scarce, and tumour biology evolves under therapeutic pressure.
Jovana Zivanovic, Jules Zhang-Yin
doaj +1 more source
Circulating tumor DNA in patients with cancer: insights from clinical laboratory
Advances in Laboratory MedicineBlood-based circulating tumor DNA (ctDNA) analysis has emerged as a highly relevant non-invasive method for molecular profiling of solid tumors, offering valuable information about the genetic landscape of cancer.
Illana Francisco J. +13 more
doaj +1 more source
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
Journal of Hematology & Oncology, 2019 Background Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation sequencing technologies.
Hitendra Patel +7 more
doaj +1 more source
BMC Cancer, 2018 Background Circulating tumour DNA (ctDNA) may serve as a measure of tumour burden and a useful tool for non-invasive monitoring of cancer. However, ctDNA is not always detectable in patients at time of diagnosis of metastatic disease. Therefore, there is
Ashleigh C. McEvoy +10 more
doaj +1 more source